PL369305A1 - Combinations comprising a selective cyclooxygenase-2 inhibitor - Google Patents

Combinations comprising a selective cyclooxygenase-2 inhibitor

Info

Publication number
PL369305A1
PL369305A1 PL02369305A PL36930502A PL369305A1 PL 369305 A1 PL369305 A1 PL 369305A1 PL 02369305 A PL02369305 A PL 02369305A PL 36930502 A PL36930502 A PL 36930502A PL 369305 A1 PL369305 A1 PL 369305A1
Authority
PL
Poland
Prior art keywords
inhibitor
combinations
growth factor
factor receptor
receptor tyrosine
Prior art date
Application number
PL02369305A
Other languages
English (en)
Polish (pl)
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL369305A1 publication Critical patent/PL369305A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL02369305A 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor PL369305A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34473401P 2001-10-25 2001-10-25
US34473501P 2001-10-25 2001-10-25
US33603301P 2001-11-15 2001-11-15

Publications (1)

Publication Number Publication Date
PL369305A1 true PL369305A1 (en) 2005-04-18

Family

ID=27407094

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02369305A PL369305A1 (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor

Country Status (22)

Country Link
US (2) US20050043409A1 (enExample)
EP (1) EP1441714B1 (enExample)
JP (1) JP2005506366A (enExample)
KR (1) KR100954625B1 (enExample)
CN (1) CN100506224C (enExample)
AT (1) ATE381930T1 (enExample)
AU (2) AU2006252156A1 (enExample)
BR (1) BR0213486A (enExample)
CA (1) CA2464309C (enExample)
CY (1) CY1108045T1 (enExample)
DE (1) DE60224299T2 (enExample)
DK (1) DK1441714T3 (enExample)
ES (1) ES2295428T3 (enExample)
HU (1) HUP0600235A3 (enExample)
IL (1) IL161462A0 (enExample)
MX (1) MXPA04003878A (enExample)
NZ (2) NZ552335A (enExample)
PL (1) PL369305A1 (enExample)
PT (1) PT1441714E (enExample)
RU (1) RU2333754C2 (enExample)
SI (1) SI1441714T1 (enExample)
WO (1) WO2003035047A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
BRPI0413876A (pt) 2003-08-29 2006-10-24 Pfizer tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
CA2539230A1 (en) * 2003-09-23 2005-03-31 Novartis Ag Combinations of a vegf receptor inhibitor with other therapeutic agents
WO2005027972A2 (en) * 2003-09-23 2005-03-31 Novartis Ag Combination of a vegf receptor inhibitor with a chemotherapeutic agent
WO2005063739A1 (en) 2003-12-23 2005-07-14 Pfizer Inc. Novel quinoline derivatives
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
CN101415422B (zh) * 2006-02-09 2012-11-07 第一三共株式会社 抗癌药用组合物
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
MD565Z (ro) * 2012-05-23 2013-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Procedeu de tratare a seminţelor de sfeclă de zahăr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100558356C (zh) * 1996-10-15 2009-11-11 G.D.瑟尔公司 应用环加氧酶-2抑制剂治疗和预防肿瘤形成的方法
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
IL143870A0 (en) * 1998-12-23 2002-04-21 Searle & Co Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE60031127T2 (de) * 1999-08-12 2007-02-01 Wyeth Holdings Corp. Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs
ES2238324T3 (es) * 1999-12-03 2005-09-01 Pfizer Products Inc. Derivados heterocicloalquilsulfonilpirazol como agentes antiinflamatorios/analgesicos.
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
WO2001060365A1 (en) * 2000-02-17 2001-08-23 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JP2003523390A (ja) * 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
WO2001064669A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer

Also Published As

Publication number Publication date
US20050043409A1 (en) 2005-02-24
KR100954625B1 (ko) 2010-04-27
CA2464309C (en) 2012-01-03
EP1441714B1 (en) 2007-12-26
BR0213486A (pt) 2005-05-10
KR20040048992A (ko) 2004-06-10
ES2295428T3 (es) 2008-04-16
CA2464309A1 (en) 2003-05-01
MXPA04003878A (es) 2004-07-08
CY1108045T1 (el) 2013-09-04
HK1068261A1 (en) 2005-04-29
US20110046190A1 (en) 2011-02-24
SI1441714T1 (sl) 2008-06-30
HUP0600235A3 (en) 2008-04-28
RU2333754C2 (ru) 2008-09-20
IL161462A0 (en) 2004-09-27
CN100506224C (zh) 2009-07-01
JP2005506366A (ja) 2005-03-03
WO2003035047A3 (en) 2003-10-23
AU2010200433A1 (en) 2010-02-25
NZ552335A (en) 2008-11-28
DE60224299D1 (de) 2008-02-07
RU2004116069A (ru) 2005-06-10
AU2006252156A1 (en) 2007-01-18
PT1441714E (pt) 2008-03-10
HUP0600235A2 (en) 2007-02-28
DE60224299T2 (de) 2008-12-11
NZ532418A (en) 2007-02-23
WO2003035047A2 (en) 2003-05-01
DK1441714T3 (da) 2008-03-31
CN1575168A (zh) 2005-02-02
ATE381930T1 (de) 2008-01-15
EP1441714A2 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
IL154949A0 (en) Imidazole derivatives as raf kinase inhibitors
MY151032A (en) Treatment of tnf? related disorders
GB0121490D0 (en) Ciompounds
WO2004050026A3 (en) Compositions and methods for treating prostate cancer
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
WO2003049702A3 (en) Vanilloid receptor ligands and their use in treatments
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
CY1108045T1 (el) Συνδυασμοι που περιλαμβανουν εναν επιλεκτο αναστολεα της κυκλοοξυγενασης-2
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
GB0121494D0 (en) Compounds
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
MXPA02001204A (es) Compuestos calciliticos.
WO2002074756A3 (de) Urokinase-inhibitoren
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
IL160382A0 (en) Use of 4-pyridylmethylphthalazines for cancer treatment
BRPI0411126A (pt) derivados de 1,3,4-triaza-fenaleno e 1,3,4,6-tetraazafenaleno
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
WO2001079505A3 (en) INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY
AU2002348101A1 (en) Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
WO2004044226A3 (en) Induction of cellular senescence by cdk4 disruption for tumor supression and regression
MXPA04002407A (es) Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer.
UA41034A (uk) Спосіб лікування хворих із злоякісними пухлинами сечового міхура
AU2013204147A1 (en) Treatment of TNFalpha related disorders

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)